Business Context and Reporting Period
This Form 8-K filing by Drugs Made In America Acquisition II Corp. (DMII), a Cayman Islands-based emerging growth company, reports events occurring between September 2025 and February 28, 2026. The report focuses on Item 5.02 regarding the departure of directors and officers and the appointment of a new CEO following a governance dispute involving the Company's Sponsor.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or operating margins. However, it discloses specific cash movements related to the Sponsor:
- Total Withdrawal (Sept 2025): $1,100,000 withdrawn from the working capital account.
- Allocation of Withdrawal: $325,000 used to repay a working capital note; $208,000 used to repay offering costs/expenses.
- Overpayment Amount: Approximately $566,269 identified as an overpayment to the Sponsor.
- Additional Withdrawal (Sept-Dec 2025): No less than $200,000 withdrawn for expenses unrelated to the Company.
Material Changes
The primary material change is the removal of Lynn Stockwell as Chief Executive Officer, Executive Chair, and Board member, effective February 28, 2026. This action was taken after the Board directed the Sponsor to return the "Overpayment Amount" and learned the Sponsor could not repay the funds. Consequently, Roger Bendelac was appointed as the new Chief Executive Officer effective immediately upon Ms. Stockwell's resignation.
Outlook, Risks, and Management Commentary
Management Commentary: The Board acted to address the Sponsor's inability to return funds withdrawn for non-company expenses. Mr. Bendelac, a 69-year-old executive with over 30 years of experience in investment banking and corporate advisory, was appointed to lead the Company. His compensation has not yet been determined and will be disclosed in a future filing.
Risks and Contingencies: The filing highlights a significant governance risk involving the misappropriation or unauthorized use of working capital by the Sponsor. The Company faces a contingency regarding the recovery of the Overpayment Amount and the additional $200,000+ withdrawn for unrelated expenses, which the Sponsor has indicated it cannot repay.
Investor Verification Checklist
- Verify the status of the $566,269 overpayment and the additional $200,000+ withdrawn for unrelated expenses.
- Confirm the terms of the new compensation arrangement for CEO Roger Bendelac once disclosed.
- Review the Company's remaining working capital and liquidity position following the Sponsor withdrawals.
- Monitor for any legal actions or further disclosures regarding the Sponsor's conduct.